TOPCorporate InformationHistory

1975 September
The Company founded in Kobe, Japan
Mikage Plant established at Higashinada-ku, Kobe
1976 December Development of purification method of Urokinase
1977 April Research Laboratories established at Higashinada-ku, Kobe
1983 October Manufacture of Urokinase product and bulk approved
1985 January Import of human Growth Hormone (hGH) approved in Japan
1986 June
Seishin Plant established at Nishi-ku, Kobe
Research Institute established at Nishi-ku, Kobe
1992 October IPO (listed on the over-the-counter stock market in Japan)
1993 April
Manufacture of recombinant hGH product, Growject® Inj. 4IU, approved
Research Laboratories established in northwest Kobe
1994 March Manufacture of Ulinastatin bulk substance approved
1995 March Listed on the Second Section of the Osaka Securities Exchange
1997 October Alliance established with Mochida Pharmaceutical Co., Ltd. for supply of urine-derived products.


Alliance established with Sumitomo Pharmaceuticals Co., Ltd. (current Dainippon Sumitomo Pharmaceuticals Co., Ltd.) for co-marketing of Growject® Inj. 4IU
Manufacture of Macrophage Colony Stimulating Factor, Leucoprol®, started
Marketing approval of Growject® 8mg
Growject® approval expanded for Turner indication
2000 May
Kobe Plant established in northwest Kobe
Growject® 8mg and Growject Pen launched
2003 August Alliance established with Osiris Therapeutics, Inc. (USA) for its technology on the use and manufacture of human mesenchymal stem cells
2008 April Murotani Plant established at northwest Kobe
2009 July Growject® approval expanded for adult growth hormone deficiency
2010 January Marketing approval of “Epoetin alfa BS Inj. JCR” obtained in Japan for treatment of renal anemia
2011 March Listed on the Second Section of the Tokyo Stock Exchange
2012 August Growject® approval expanded for short stature associated with small for gestational age
2013 May
Kobe API Plant established at northwest Kobe
Listed on the First Section of the Tokyo Stock Exchange
2014 January Japanese corporate name changed to "JCRファーマ"
2015 September Marketing approval of TEMCELL® HS Inj., The first Allogeneic Regenerative Medicine in Japan
2016 April

Clinical Trial Material Manufacturing Center and Cell Processing Center established at northwest Kobe
Marketing approval for a new liquid formulation of Growject®
2017 September Business and Capital Alliance agreement conducted with MEDIPAL HOLDINGS CORPORATION
2018 January
JCR USA, Inc. established
Marketing Approval of “Agalsidase Beta BS I.V. Infusion JCR” for Fabry disease
2019 September Marketing Approval of “Darbepoetin Alfa BS Injection JCR”, a Long-Acting Erythropoiesis-Stimulating Agent.
2020 April Acquire ArmaGen, Inc.